BridgeBio
Pfizerās tafamidis faces competition from Alnylam and BridgeBio in rare disease market
Anika Sharma
Alnylam and BridgeBio are poised to enter the highly lucrative transthyretin amyloidosis cardiomyopathy (ATTR-CM) market with the backing of an ...
BridgeBio Reports Improved Data for ATTR Cardiomyopathy Drug
SG Tylor
Source – BridgeBio BridgeBio is preparing to seek FDA approval for its acoramidis drug to treat transthyretin amyloidosis (ATTR) cardiomyopathy, ...
